MedPath

Therapeutic effect of dalfampridine on patients with Devic syndrome

Phase 2
Recruiting
Conditions
Devic.
Neuromyelitis optica [Devic]
G36.0
Registration Number
IRCT20210917052506N1
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
70
Inclusion Criteria

Age between 16 to 65 years
T25FW-based gait disorder: Test between 5 and 60 seconds
Definitive diagnosis of Devic disease based on wingerchuc criteria
No other neurological or psychological disease
No relapse during the three months prior to enrollment

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath